Featured Products
- HCC-78
- HDLM-2
- DOHH-2
- L-540
- MX-1
- NALM-6
- NB-4
- CAL-51
- SNB-19
- KYSE-520
- MKN-45
- BA/F3
- MS-5
- HCEC-B4G12
- NK-92
- PA-TU-8988S
- MONO-MAC-1
- PA-TU-8902
- Human Microglia
- Human Hepatic Stellate Cells
- Human Skeletal Muscle Cells (DMD)
- Human Schwann Cells
- Human Oral Keratinocytes (HOK)
- Human Cardiomyocytes
- Human Small Intestinal Epithelial Cells
- Human Colonic Epithelial Cells
- Human Intestinal Fibroblasts
- Primary Human Large Intestine Microvascular Endothelial Cells
- Human Small Intestinal Microvascular Endothelial Cells
- Human Retinal Pigment Epithelial Cells
- Human Hepatocytes
- Cynomolgus Monkey Lung Microvascular Endothelial Cells
- Cynomolgus Monkey Vein Endothelial Cells
- C57BL/6 Mouse Primary Mammary Epithelial Cells
- C57BL/6 Mouse Vein Endothelial Cells
- Rat Primary Kidney Epithelial Cells
- Rat Gingival Epithelial Cells
- Rabbit Lung Endothelial Cells
Our Promise to You
Guaranteed product quality, expert customer support
ActoFactor™ Recombinant Human Insulin-like growth factor binding protein 4
- Specification
- Recommended Products
Cat.No.
CSC-CTK0204
Description
IGF-BPs control the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP4 is the major IGF-BP produced by osteoblasts, and is also found in the epidermis, ovarian follicles, and other tissues. IGF-BP4 inhibits the activity of IGF-I and IGF-II by binding in a manner that results in the formation of complexes with reduced ability to signal through cell surface IGF receptors. IGF-BP4 can inhibit the growth of chick pelvis cartilage and HT29 colon adenocarcinoma cells by blocking the mitogenic actions of IGFs, and has also been shown to reduce colony formation by colorectal cancer cells via an IGF independent pathway. The biological effects of IGF-BP4 can be regulated by Pregnancy Associated Plasma Protein A (PAPP- A), which reduces IGF-BP4/IGF binding affinity by proteolytically cleaving IGF-BP4. The modulation of IGF-BP4 activity by PAPP-A is an important component in the regulation of ovarian folliculogenesis and in the growth inhibition of responding ovarian cancer cells. Recombinant human IGF-BP4 is a 25.8 kDa protein consisting of 237 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain.
Species
Human
Product Overview
Human IGFBP4 expressed in Insect cells
Molecular Mass
25.8 kDa
Size
CAT# CSC-CTK0204-20 (20 μg); CAT# CSC-CTK0204-100 (100 μg)
Expression System
Insect cells
Purity
Greater than 95% as determined by SDS-PAGE and HPLC analysis.
Activity
Determined by its ability to inhibit IGF-I induced proliferation of FDC-P1 cells.
Endotoxin Level
Less than 1 EU/μg.
Formulation
Lyophilized from a sterile-filtered solution with no additives.
Reconstitution
Please centrifuge product before opening vial. The lyophilized protein should be reconstituted with distilled, sterile water to a concentration of 0.1-1.0 mg/ml. For further dilution, carrier protein (0.1% BSA or HSA) should be added to avoid loss of bioactivity.
Storage & Stability
The lyophilized protein, though stable at room temperature for up to 3 weeks, is best stored desiccated at -20°C. Reconstituted protein should be used immediately or stored long-term in undiluted working aliquots at -20°C. For long-term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Avoid repeated freeze-thaw cycles.
Citation Guidance
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.
- Q & A
- Customer Review
Customer Support & Price Inquiry
